Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1231P - Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study
Presenter: Kumar Prabhash
Session: Poster session 04
1233P - Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC
Presenter: Apostolos Klinakis
Session: Poster session 04
1234P - Stage migration in resectable NSCLC
Presenter: Guus Heuvel
Session: Poster session 04
1235P - Pathologic response as a surrogate endpoint for event-free survival in neo-adjuvant immunotherapy trials of resectable non-small cell lung cancer: A subgroup analysis
Presenter: Nancy Huang
Session: Poster session 04
1236P - ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers
Presenter: Sam Khan
Session: Poster session 04
1237P - Association of LRRC15 protein expression with 5-year survival in lung adenocarcinoma patients
Presenter: Jessie Woon
Session: Poster session 04
1238TiP - Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL)
Presenter: Siu Ching Li
Session: Poster session 04